Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseases.
Due to the dramatic improvements in cure and survival of young patients of reproductive age suffering from malignant or systemic disease, the preservation of fertility and ovarian function during cytostatic treatment has become of increased importance during the last decade. Pharmacological therapy with GnRH analogues and the cryopreservation of ovarian tissue are discussed in this context. The value of these treatment procedures and their potential clinical applications are critically reviewed in this article.
Mattle
Verena
V
Department of Gynecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Behringer
Karolin
K
Engert
Andreas
A
Wildt
Ludwig
L
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D002648:Child; D015925:Cryopreservation; D005260:Female; D005298:Fertility / Q000187:drug effects; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010053:Ovary / Q000637:transplantation; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone